News

Long-Term clinical outcome study of CounterCOVID patients published

“Lower mortality rate, better clinical status, and shorter duration of invasive ventilation were observed in hospitalised patients with COVID-19 treated with imatinib during a 90-day follow-up” [...]

First Patients Enter Clinical Trial of Impentri for COVID-19 ARDS

“The Impentri IMI2 consortium are pleased to announce the first patients have been dosed in Amsterdam, NL as part of its clinical trial to investigate the safety [...]

CounterCOVID study shows imatinib significantly reduces mortality by 49% in patients with COVID-19

Results published on Friday 18 June in The Lancet Respiratory Medicine show that oral imatinib, currently used to treat cancers, reduces mortality by 49% in hospitalized COVID-19 [...]

Could this cancer drug fight fluid build-up in the lungs of COVID patients?

IMPENTRI will look for clinical proof of the benefit of imatinib in Covid-19 acute respiratory distress syndrome The build-up of fluid in the lungs is common among [...]

IMI2 Grant awarded to fund clinical study of imatinib in the treatment of COVID-19-associated ARDS

CAMBRIDGE, UK AND DUBLIN, IRELAND, May 13 2020 / / — Exvastat (Ireland) Ltd, a privately held biopharmaceutical company backed by Cambridge Innovation Capital, today announced the [...]